Results 81 to 90 of about 31,184 (259)

Minocycline and bone marrow–derived mononuclear cells as potential therapeutics for hereditary retinal degenerations

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To assess in Royal College of Surgeons (RCS) rats if the combination of two previously documented neuroprotective strategies: minocycline administration and bone marrow–derived mononuclear cells (BM‐MNCs) intravitreal transplantation, offers enhanced neuroprotection compared with each treatment alone.
Alba Videla‐Ristol   +6 more
wiley   +1 more source

The impact of systemic long‐term medications for the development of age‐related macular degeneration

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä   +3 more
wiley   +1 more source

Association of treated neovascular AMD with disability and mood disorders: A longitudinal nationwide study

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To describe the associations of treated neovascular AMD with the risk of disability, falls, fractures and mood disorders in a large sample representative of the French population. Methods Analyses were based on 77 582 individuals belonging to the ‘Echantillon Généraliste des Bénéficiaires’, a 1/97 random sample of the French population,
Cécile Delcourt   +6 more
wiley   +1 more source

Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy

open access: yesCase Reports in Ophthalmology, 2017
Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation.
Thomas Bertelmann   +3 more
doaj   +1 more source

Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis

open access: yes, 2015
Douglas K Sigford,1 Shivani Reddy,1 Christine Mollineaux,2 Shlomit Schaal1 1Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, 2Department of Ophthalmology and Visual Science, University of Kentucky, Lexington ...
Schaal S   +3 more
core  

THE MACULAR HOLE AFTER INTRAVITREAL INJECTIONS OF RANIBIZUMAB IN A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION – A CASE STUDY

open access: yes, 2013
There are two forms of age-related macular degeneration (AMD), the dry one and the exudative one. The exudative form of AMD can be treated using repeated intravitreal injections of antibodies against vascular endothelial growth factor (VEGF).
Michał Biskup   +2 more
core   +1 more source

The impact of coronary artery bypass grafting on the short‐ and long‐term development and progression of diabetic retinopathy: A Danish national matched cohort study

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Diabetic retinopathy (DR) is a frequent long‐term complication of diabetes. While hemodynamic changes are known risk factors for DR, the effect of coronary artery bypass grafting (CABG) on the development of DR is poorly investigated.
Lukas Greve Maschoreck   +16 more
wiley   +1 more source

Intravitreal Injection—Technique and Safety

open access: yesAsia-Pacific Journal of Ophthalmology, 2015
Intravitreal (IVT) injection of therapeutic agents has become one of the most commonly performed procedures in ophthalmology. Over the past decade, a number of guidelines have been published that recommend proper techniques to increase the safety of IVT injections.
Timothy Y Y, Lai   +3 more
openaire   +2 more sources

Intravitreal bevacizumab injections for diabetic macular edema – predictors of response: a retrospective study

open access: yes, 2016
Lavnish Joshi,1–3 Asaf Bar,4 Oren Tomkins-Netzer,1,3 Satish Yaganti,1 Jiten Morarji,1 Panayiotis Vouzounis,1 Sophie Seguin-Greenstein,1,4 Simon R Taylor,3,5 Sue Lightman1,3 1Department of Clinical Ophthalmology, UCL Institute of Ophthalmology and ...
Tomkins-Netzer O   +8 more
core  

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy